Director/PDMR Shareholding | 22-Feb-2024 | 15:30 | RNS |
ViiV LAI superior to orals in adherence-challenged | 21-Feb-2024 | 07:00 | RNS |
Julie Brown - External Appointment | 20-Feb-2024 | 09:01 | RNS |
Director/PDMR Shareholding | 19-Feb-2024 | 15:30 | RNS |
Director/PDMR Shareholding | 15-Feb-2024 | 15:32 | RNS |
GSK completes acquisition of Aiolos Bio | 15-Feb-2024 | 07:00 | RNS |
Director/PDMR Shareholding - Replacement | 13-Feb-2024 | 16:45 | RNS |
Director/PDMR Shareholding | 13-Feb-2024 | 15:40 | RNS |
Director/PDMR Shareholding | 13-Feb-2024 | 15:35 | RNS |
Director/PDMR Shareholding | 13-Feb-2024 | 15:30 | RNS |
FDA accepts Arexvy filing for adults 50-59 at risk | 06-Feb-2024 | 07:10 | RNS |
Shingrix 18+ at risk China filing review accepted | 06-Feb-2024 | 07:05 | RNS |
GSK presents positive DREAMM-7 phase III data | 06-Feb-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 01-Feb-2024 | 15:30 | RNS |
Total Voting Rights | 01-Feb-2024 | 15:00 | RNS |
Currency | UK Pounds |
Share Price | 1,761.00p |
Change Today | 27.50p |
% Change | 1.59 % |
52 Week High | 1,767.50 |
52 Week Low | 1,316.00 |
Volume | 14,302,691 |
Shares Issued | 4,144.92m |
Market Cap | £72,992m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 5 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 16-May-24 | 22-Feb-24 |
Paid | 11-Jul-24 | 11-Apr-24 |
Amount | 15.00p | 16.00p |
Time | Volume / Share Price |
16:36 | 605,610 @ 1,761.00p |
16:36 | 605,610 @ 1,761.00p |
11:30 | 2,800,000 @ 1,736.00p |
11:30 | 2,800,000 @ 1,736.00p |
16:47 | 18,589 @ 1,762.54p |
You are here: research